IOTA Pharma Competitors and Similar CompaniesClear all

IOTA Pharma's competitors and similar companies include UCB, Cipla, CSL Behring and Mankind Pharma.

	IOTA Pharma TA Pharmaceuticals is a pharmaceutical discovery company.	UCB UCB is a company that provides biopharmaceutical research and development solutions for neurological and immunological conditions.	Cipla Cipla is a pharmaceutical company focused on the development, manufacturing, and distribution of medications and healthcare products.	CSL Behring CSL Behring is a provider of life-saving medicines.	Mankind Pharma Mankind Pharma is a pharmaceutical company developing, commercializing, and delivering medicines.
Founding Date	Founding Date 2007	Founding Date 1928	Founding Date 1935	Founding Date 1904	Founding Date 1995
Type	Type Private	Type Public	Type Public	Type Subsidiary	Type Private
Tags	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma
Locations	Locations Cambridge, GB HQ	Locations Brussels, BE HQ Melbourne, AU Vienna, AT Braine L'alleud, BE Braine L'alleud, BE Leuven, BE São Paulo, BR see more	Locations Mumbai, IN HQ Melbourne, AU Antwerpen, BE São Paulo, BR São Paulo, BR Unterhaching, DE Nairobi, KE see more	Locations King of Prussia, US HQ Broadmeadows, AU Parkville, AU Parkville, AU Wien, AT Mechelen, BE see more	Locations New Delhi, IN HQ
Employees	Employees 2	Employees 9,052	Employees 27,764	Employees 7,5692% decrease	Employees 16,2532% increase
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) €7.4b (FY, 2025)	Revenue (est.) ₹277.1b (FY, 2026)	Revenue (est.) $7.9b (FY, 2020)	Revenue (est.) N/A
Cost of goods	Cost of goods N/A	Cost of goods €1.4b (FY, 2025)	Cost of goods ₹95.5b (FY, 2026)	Cost of goods N/A	Cost of goods N/A
Gross profit	Gross profit N/A	Gross profit €7.2b (FY, 2025)	Gross profit ₹195b (FY, 2026)	Gross profit $4.5b (FY, 2020)	Gross profit N/A
Net income	Net income N/A	Net income €1.6b (FY, 2025)	Net income ₹38.7b (FY, 2026)	Net income N/A	Net income N/A
Operating ⚠
Countries	Countries N/A	Countries 35 (FY, 2019)	Countries N/A	Countries 100 (Dec, 2020)	Countries N/A